Nuvig Therapeutics
PrivateLast Round
Series B
Dec 5, 2024
Total Funding Raised
$208M
Company Overview
Nuvig Therapeutics is a biotechnology company that develops innovative immunomodulatory therapies to restore immune homeostasis and treat chronic inflammatory and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Nuvig Therapeutics Comparables
Compare Nuvig Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Immunovant | 78% | |
| Dianthus Therapeutics | 76% | |
| Annexon Biosciences | 75% |
Nuvig Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Dec 5, 2024 | ||||
| Series A | May 11, 2022 |
Key People
Founding team and executive leadership
Nuvig Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Aberdeen Group plc | Series B |
| Digitalis Ventures | Series A, Series B |
| RM Global Partners | Series B |
| abrdn Inc. | Series B |
| B Capital Group | Series B |
| TD Securities | Series B |
| Blue Owl Capital | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 18, 2025
Celia J.F. Lin, M.D. appointed as Chief Medical Officer.
- Sep 9, 2025
James Mackay appointed as Independent Board Chair.
Nuvig Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Nuvig Therapeutics's valuation, stock price, and market status.
Is Nuvig Therapeutics a public or private company?
Nuvig Therapeutics is a private company.
What is the current stock price of Nuvig Therapeutics?
Nuvig Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Nuvig Therapeutics worth (valuation)?
Valuation information for Nuvig Therapeutics is not publicly available.
Can I buy Nuvig Therapeutics stock?
Nuvig Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Nuvig Therapeutics's last funding round?
Nuvig Therapeutics's most recent funding round was Series B on December 5, 2024.
Who are the main investors in Nuvig Therapeutics?
Key investors in Nuvig Therapeutics include TD Securities, Blue Owl Capital, Norwest Venture Partners, Novo Holdings, Sanofi Ventures.
Will Nuvig Therapeutics IPO soon?
No public IPO plans have been announced for Nuvig Therapeutics.
How can I track Nuvig Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Nuvig Therapeutics's secondary market activity and sign up for updates.